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ABSTRACT 
Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the 
standard of care. Although surgical resection in selected patients may potentially be curative, systemic therapy is the 
only choice of treatment for most patients with metastatic colorectal cancer. Anti-epidermal growth factor receptor 
(anti-EGFR) monoclonal antibody has established its role in the systemic therapy of metastatic colorectal cancer 
through multiple well-designed clinical trials and yet, the optimal use of anti-EGFR monoclonal antibody is undefined. 
This article serves to review the available evidence for anti-EGFR monoclonal antibodies and to speculate optimal 
strategy for their uses. 
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1. Introduction 
Colorectal cancer is the third most common cancer in 
men and the second in women worldwide. Every year, 
about 608,000 deaths are estimated, making colorectal 
cancer the fourth most common cause of cancer-related 
death [1]. Among patients with colorectal cancer, around 
40% of patients present with or will eventually develop 
distant metastasis. The principal modality of treatment 
for patients with metastatic disease is systemic therapy 
and approved sole or combination options include: 5- 
fluorouracil, capecitabine, oxaliplatin, irinotecan, bevaci-
zumab, cetuximab and panitumumab. Among all these 
options, only the anti-epidermal growth factor receptor 
(anti-EGFR) monoclonal antibodies, cetuximab and pani-
tumumab, have proven efficacy in early as well as late 
lines of therapy. 
1.1. Epidermal Growth Factor Receptor 
(EGFR) 
The ErbB family of receptors, which is also known as the 
human epidermal growth factor receptor (HER), plays a 
critical role in carcinogenesis. Being the first receptor 
identified in the family, EGFR is also known as the type 
I receptor tyrosine kinase or ErbB1/HER1. The other 
member receptors in this family are ErbB2 (HER2/neu), 
ErbB3 (HER3) and ErbB4 (HER4) [2-4]. 
The EGFR is located on the cell surface and is struc- 
turally composed of an extracellular ligand-binding do-
main, a transmembrane segment and an intracellular ty-
rosine kinase domain. A variety of ligands, including 
epidermal growth factor, transforming growth factor-α, 
amphiregulin and epiregulin, is able to bind to EGFR. 
Upon ligand binding, EGFR forms homo- or heterodimers 
with other members of the ErbB family resulting in 
autophosphorylation of the intracellular domain and sub-
sequent activation of downstream intracellular signaling 
cascade [5,6]. 
The Ras/Raf/ mitogen-activated protein kinase (MAPK), 
the PI3K/AKT and the Jak2/Stat3 pathways are major 
downstream signaling pathways that are crucial for can-
cer cell proliferation, survival, invasion, metastasis and 
neo-angiogenesis [7]. 
1.2. Anti-EGFR Monoclonal Antibody 
Monoclonal antibody directed at the EGFR was first 
studied on mice in the 1980’s [8,9] but not until February 
2004 when the first anti-EGFR monoclonal antibody was 
approved for treating metastatic colorectal cancer in hu-
man. Monoclonal antibodies, such as cetuximab and 
panitumumab, bind to the extracellular domain of EGFR 
and, hence block the ligand-binding induced receptor 
dimerization as well as tyrosine kinase activation [10]. In 
addition, cetuximab, being a chimeric antibody, is able to 
elicit antibody-dependent cellular cytotoxicity against 
cancer cells [11,12] *Corresponding author. 
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2. Anti-EGFR Antibodies in Key Phase III 
Studies 
KRAS is a GTP-binding protein which plays a crucial 
role in the downstream intracellular signaling cascade of 
various receptor tyrosine kinases including the EGFR. 
Activating mutation of KRAS occurs in ~40% of patients 
with colorectal cancer. Mutations in the KRAS oncogene 
will lead to constitutive activation of the KRAS protein 
independent of the upstream regulation and thus, may 
affect the efficacy of anti-EGFR antibodies. In the fol-
lowing section, evidence from the key phase III clinical 
trials using anti-EGFR antibodies will be evaluated, with 
special attention to their differential activities in KRAS 
wild-type and mutant tumors (Table 1). 
2.1. Anti-EGFR Antibodies in the First-Line  
Setting 
2.1.1. The Crystal Study 
The CRYSTAL study was the first to demonstrate over-
all survival benefit with the use of cetuximab in the 
first-line treatment of metastatic colorectal cancer. It was 
a phase III open-label, randomized, multi-center study 
that compared cetuximab plus FOLFIRI and FOLFIRI 
alone [13]. 1198 patients with EGFR-expressing adeno-
carcinoma were enrolled. After a median follow-up of 
around 30 months, patients in the cetuximab-FOLFIRI 
arm had significantly prolonged progression-free survival 
(8.9 vs 8.0 months; HR, 0.85; p = 0.048). The high pro-
portion of patients received post-study chemotherapy in 
 
Table 1. Clinical efficacy of anti-EGFR antibody in phase III clinical trials: stratified according to KRAS status. 
KRAS Wild Type KRAS MUTANT 
Study Regimen Primary End Point
No. of Patients ORR (%)
mPFS
(mo)
mOS
(mo) No. of Patients ORR (%) 
mPFS
(mo)
mOS
(mo)
First Line 
FOLFIRI PFS 350 39.7* 8.4* 20* 183 36.1 7.7 16.7
CRYSTAL 
[14] 
Cetuximab + FOLFIRI  316 57.3 9.9 23.5 214 31.3 7.4 16.2
FOLFOX PFS 331 48 8* 19.7 219 40 8.8* 19.3
PRIME 
[16] 
Panitumumab + FOLFOX  325 55 9.6 23.9 221 40 7.3 15.5
FOLFOX/XELOX OS 367 57* 8.6 17.9 268 NR NR 14.8
COIN 
[19] 
Cetuximab + FOLFOX/XELOX  362 64 8.6 17 297 NR NR 13.6
FLOX PFS 97 47 8.7 22 58 40 7.8 20.4
NORDIC 
[20] 
Cetuximab + FLOX  97 46 7.9 20.1 72 49 9.2 21.1
Second Line 
Irinotecan OS 2.8  
EPIC 
[23] 
Cetuximab + Irinotecan  
NR 
4  
NR 
FOLFIRI OS&PFS 294 10 3.9* 12.5 248 14 4.9 11.1
20050181 
[24] 
Panitumumab + FOLFIRI  303 35 5.9 14.5 238 13 5 11.8
Third Line 
BSC OS 113 0 1.9* 4.8* 76 0 1.8 4.6 
CO.17 
[27] 
Cetuximab + BSC  117 12.8 3.7 9.5 75 1.2 1.8 4.5 
BSC PFS 119 0 1.7* 7.6 100 0 1.7 4.4 
20020408 
[29] 
Panitumumab + BSC  124 17 2.8 8.1 84 0 1.7 4.9 
ORR: overall response rate; mPFS: median progression-free survival; mOS: median overall survival; mo: months. *statistical significant. 
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both arms might explain why no statistically significant 
difference in overall survival was achieved. Indeed, anti- 
EGFR antibody was given to 25.4% and 6.2% of patients 
in the FOLFIRI and cetuximab-FOLFIRI arm, respec- 
tively, after progression. Increasing grade of skin toxicity 
correlates with longer progression-free survival in cetuxi-
mab-treated patients. 
Further retrospective analyses confirmed KRAS muta-
tional status as a strong predictor of clinical outcomes in 
patients treated with cetuximab. The addition of cetuxi-
mab to FOLFIRI in patients with KRAS wild-type dis-
ease resulted in significant improvements in overall sur-
vival (23.5 vs 20.0 months; HR, 0.796; p = 0.0093), pro-
gression-free survival (9.9 vs 8.4 months; HR, 0.696; p = 
0.0012) and response rate (57.3% vs 39.7%; OR, 2.069; 
p < 0.001) [14] In the pooled analysis of the CRYSTAL 
and OPUS trials, similar magnitude of benefit were 
demonstrated for overall survival (HR, 0.81; p = 0.0062), 
progression-free survival (HR, 0.66; p < 0.001) and re-
sponse rate (OR, 2.16; p < 0.0001) [15]. In both analyses, 
BRAF status was shown to be prognostic rather than 
predictive [14,15]. 
2.1.2. The PRIME Study 
A phase III, open-label, randomized, multi-center study 
that evaluated the role of panitumumab with FOLFOX4 
in the first-line treatment of metastatic colorectal cancer 
[16]. While both the PRIME study and the CRYSTAL 
study recruited unselected patients with respect to the 
KRAS status, a prospective analysis on treatment out-
comes according to KRAS status was included only in 
the former. 93% of the 1,183 randomly assigned patients 
had KRAS status available. KRAS wild-type tumor 
comprised 60% of the whole study population. Although 
not stratified in the random assignment, this proportion 
was preserved in both the experimental and control arm. 
Within the KRAS wild-type stratum, progression-free 
survival, the primary endpoint of the study, was signifi-
cantly improved from 8.0 months to 9.6 months [HR, 
0.80; p = 0.02]. The overall survival, the secondary end-
point, was increased from 19.7 months to 23.9 months 
but no statistical significant difference was reached. 
The overall survival result should be interpreted with 
data on post-progression treatment: 8% and 18% of pa-
tients in the panitumumab-FOLFOX4 arm and FOLFOX4 
arm received anti-EGFR antibodies, respectively. More 
patients in the FOLFOX4 arm (62%) than those in the 
panitumumab-FOLFOX4 arm (53%) received subsequent 
chemotherapy. Bevacizumab was also given in 12% - 
15% of patients. 
Similar to the result of the biomarker analysis in the 
OPUS study [17], the PRIME study has shown that 
KRAS status was predictive of panitumumab efficacy. In 
the KRAS mutant stratum, patients who received pani-
tumumab has reduced progression-free survival [HR 1.29; 
p = 0.02] and overall survival [HR, 1.24; p = 0.068]. 
However, subsequent analysis of adverse events as well 
as dose intensity did not reveal a plausible explanation 
for the detrimental effect of panitumumab on KRAS mu-
tant tumor [16,18]. 
2.1.3. The MRC COIN Study 
The MRC COIN study was the largest phase III, ran-
domized, multicenter study that compared chemotherapy 
with or without cetuximab on overall survival as the pri-
mary endpoint [19]. A prospective analysis of KRAS 
status on treatment effect and molecular analysis of 
BRAF and NRAS were also performed. One thousand 
six hundred and thirty patients were randomized and tu-
mor samples from 1316 patients were available for mo-
lecular analysis. Oxaliplatin was combined with either 
infusional 5-fluorourail or capecitabine as the chemo-
therapy backbone. Contrary to previous results with anti- 
EGFR antibodies, the overall survival and progression- 
free survival were not improved with the use of cetuxi- 
mab even in KRAS wild-type tumor. The only significant 
finding was an improvement of overall response rate 
from 57% to 64% [OR, 1.35; p = 0.049]. 
Interestingly, this largest trial on cetuximab raised the 
critical question of what is the appropriate chemotherapy 
partner with cetuximab. The addition of cetuximab to 
capecitabine-based chemotherapy resulted in increased 
toxicity, especially grade 3 or above diarrhoea (30%), 
which mandated a protocol amendment for dose reduc-
tion of capecitabine from 1000 mg/m2 to 850 mg/m2. Of 
patients taking cetuximab, numerically more treatment- 
related deaths were reported in the subgroup that re-
ceived capecitabine-based therapy. As such the dose in-
tensity of capecitabine-based therapy reduced signifi-
cantly from 85% in the control arm to 79% in the cetuxi- 
mab arm [p = 0.0021].  
Subsequent analysis also showed that the only group 
of patients that may gain benefit from cetuximab is 1) 
KRAS wild-type tumors; 2) Limited distribution of me-
tastatic disease; and 3) Treated with infusional fluorouracil. 
[HR, 0.55; p = 0.011]. 
Irrespective of treatment received, somatic mutation 
status correlated with overall survival: 14.4 months in 
KRAS mutant, 8.8 months in BRAF mutant and 20.1 
months in all wild-type. 
2.1.4. The NODIC VII Study 
The NODIC VII study concluded that cetuximab did not 
add significant benefit in the first-line treatment of me- 
tastatic colorectal cancer [20]. It was a 3-arm phase III, 
randomized, multicenter study that investigated the bene- 
fit of cetuximab and compared continuous versus inter- 
mittent regimen. The chemotherapy backbone were ox- 
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aliplatin and bolus 5-fluorouracil, also known as the 
Nordic FLOX, which is a standard regimen in the Nordic 
countries [21]. The impact of KRAS status was also in-
cluded after a protocol amendment but no sample size 
re-estimation was performed. Five-hundreds and sixty- 
six patients were randomized to ensure a greater than 
80% power to detect an increase in progression-free sur-
vival from 7 to 10 months. Knowing that this magnitude 
of benefit has never been achieved with any of the 
anti-EGFR antibodies, the conclusion of no significant 
difference is not entirely unexpected. In all the study 
arms, in both the intention-to-treat and the KRAS wild- 
type subset, the progression-free survival, overall sur-
vival and the response rate were almost identical. Unex-
pectedly, a trend towards improved progression-free sur-
vival was observed in KRAS mutant tumor. Further 
analysis that addressed the probable differential response 
in KRAS mutant tumors did not show any difference in 
efficacy for patients with codon 13 (G13D) and codon 12 
mutations treated with cetuximab. 
2.2. Anti-EGFR Antibodies in the Second-Line 
Setting 
2.2.1. The EPIC Study 
A phase III open-label, randomized study that was de-
signed to determine whether the addition of cetuximab to 
irinotecan as second-line therapy would prolong survival 
[22]. Patients were eligible if they were irinotecan-naïve 
and have failed both oxaliplatin and fluoropyrimidine in 
their first-line treatment. Although prior bevacizumab 
was allowed (bevacizumab was given in 13% of patients 
in both arms), previous exposure to anti-EGFR therapies 
were excluded.  
The study failed to meet its primary end point of im-
provement in overall survival. This was probably due to 
the fact that a substantial proportion (46.9%) of patients 
in the irinotecan alone arm subsequently received cetuxi- 
mab-based therapy. Compared with patients treated with 
irinotecan alone, those treated with cetuximab and iri-
notecan had significantly longer progression-free sur-
vival [4.0 vs 2.6 months, HR: 0.692, p < 0.0001] and 
higher overall response rate [16.4% vs 4.2%, p < 0.0001]. 
Despite longer treatment duration and more treatment- 
related toxicities, cetuximab and irinotecan were signifi-
cantly more effective in maintaining overall quality of 
life. 
The KRAS mutation status was retrospectively ana-
lyzed from 23% of patients but the progression-free sur-
vival, overall survival and response rate did not differ 
significantly in the KRAS wild-type tumor [23]. 
2.2.2. The 20050181 Study 
A phase III, open-label, randomized, multicenter study 
that compared the efficacy of panitumumab plus FOLFIRI 
versus FOLFIRI alone [24]. Patients were eligible if they 
have failed fluoropyrimidine-based therapy in the first- 
line setting. Prior treatments with irinotecan and anti- 
EGFR therapy were not allowed. Unlike the EPIC study, 
failure of oxaliplatin treatment is not required and KRAS 
status was prospectively analyzed. 
In the 1186 patients that were randomized, ninety-one 
percent of them had specimen available for KRAS status 
test. In the KRAS wild-type subgroup, the addition of 
panitumumab to FOLFIRI significantly prolonged the 
progression-free survival from 3.9 months to 5.9 months 
[HR, 0.73; p = 0.004] and improved the response rate 
from 10% to 35% [p < 0.001]. However, the difference in 
overall survival failed to reach statistical significance 
[14.5 months versus 12.5 months; HR, 0.85; p = 0.12]. 
Contrary to the result of PRIME study, panitumumab did 
not appear to have detrimental effect on response rate, 
progression-free survival and overall survival in the 
KRAS mutant subgroup. 
2.3. Anti-EGFR Antibodies in the Third-Line 
Setting 
2.3.1. The BOND Study 
In the BOND study, 329 patients who progressed during 
or within 3 months after treatment with an irinotecan- 
based regimen were randomized in 2:1 ratio to receive 
either cetuximab and irinotecan or cetuximab monother-
apy [25]. The number of prior chemotherapy was not 
restricted but around 80% of patients received study 
treatment at the third-line or beyond setting. The re-
sponse rate was significantly different, being 22.9% in 
the combination arm and 10.8% in the cetuximab mono-
therapy arm [p = 0.007]. The time to progression was 
also significantly prolonged from 1.5 months to 4.1 
months [HR: 0.54, p < 0.001]. The overall survival was 
not different significantly as patients in the cetuximab 
monotherapy arm were allowed to receive irinotecan 
upon disease progression. 
2.3.2. The NCIC CO.17 Study 
A phase III randomized, multicenter study that compared 
single agent cetuximab to best supportive care in patients 
who have failed or contraindicated to fluoropyrimidine, 
oxaliplatin and irinotecan [26]. The primary end point 
was overall survival and a total of 572 patients were 
randomized. Cetuximab prolonged the median overall 
survival from 4.6 months to 6.1 months [HR: 0.77, p = 
0.005]. The result did reflect the unconfounded benefit of 
cetuximab monotherapy since only a small proportion of 
patients went on to receive any post-progression therapy. 
Interestingly, an unplanned subgroup analysis demon-
strated that the grade of rash in patients receiving cetuxi- 
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mab strongly correlated with overall survival, being 2.6 
months in patients with no rash, 4.8 months in patients 
with grade 1 rash and 8.4 months in patients with grade 2 
rash [p < 0.001]. 
A retrospective analysis on KRAS status was subse-
quently performed on 69% of patients. In the KRAS 
wild-type subgroup, the progression-free survival, overall 
survival and response rate were significantly improved 
with cetuximab over best supportive care. The response 
rate to cetuximab monotherapy was 12.8%. In the KRAS 
mutant group, clinical outcomes were not significantly 
different between the cetuximab arm and best supportive 
care arm [27,28]. 
2.3.3. The 20020408 Study 
A phase III randomized, multicenter study on the use of 
panitumumab versus best supportive care in chemother-
apy-refractory patients [29]. Unlike the NCIC CO.17 
study, eligible patients have to fail 2 to 3 lines of chemo-
therapy, and to be exposed to a defined dose intensity of 
both oxaliplatin and irinotecan. A pre-planned analysis 
on KRAS status was included.  
463 patients were randomized and the progression-free 
survival was significantly prolonged in the panitumumab 
arm [8 weeks vs 7.3 weeks; HR, 0.54; p < 0.0001]. The 
overall survival was similar between the two study arms 
but was likely the result of the high rate and rapidity of 
cross-over after progression in the supportive-care arm. 
The objective response rate was 10% with panitumumab 
monotherapy.  
KRAS status was available for 92% of patients. In pa-
tients with KRAS wild-type tumor, the progression free 
survival, the primary end point of the study, was signifi-
cantly increased [12.3 weeks vs 7.3 weeks; HR, 0.45]. 
The overall survival differed significantly in neither of 
the KRAS subgroups. 
3. Evolving Strategies with Anti-EGFR  
Antibody 
3.1. Anti-EGFR Antibody Concurrent with 
Anti-VEGF Antibody 
Preclinical data has shown a close relationship of VEGF 
and EGFR signaling cascade and that the combine of 
both anti-VEGF and anti-EGFR therapy would be a bio-
logically plausible and attractive strategy [30-33]. 
3.1.1. The BOND 2 Study 
A phase II randomized study to evaluate the benefit of 
bevacizumab added to cetuximab and irinotecan or cetuxi-
mab alone in patients who were irinotecan-refractory [34]. 
The median numbers of regimens before study entry was 
3 in both arms. The primary end point was time to tumor 
progression and 83 patients were enrolled. In the bevaci-
zumab, cetuximab and irinotecan arm, the time to tumor 
progression was 7.3 months and the response rate was 
37%. Even in the bevacizumab and cetuximab arm, the 
time to tumor progression reached 4.9 months and the 
response rate 20%. 
3.1.2. The CAIRO 2 Study 
A phase III randomized multicenter study that recruited 
755 previously untreated patients to study the benefit of 
cetuximab added to a regimen of bevacizumab, capecit-
abine and oxaliplatin [35]. The primary end point was 
progression-free survival and KRAS was evaluated as a 
predictor of outcome. The addition of cetuximab has led 
to a significantly shorter progression-free survival [9.4 
months vs 10.7 months; HR, 1.22; p = 0.01] and inferior 
quality of life while the overall survival and response rate 
were not significantly different. In the KRAS mutant 
subgroup, the progression-free survival was shortened 
with the addition of cetuximab. 
3.1.3. PACCE Study 
A US community-based, randomized phase IIIB study 
that evaluated the efficacy and safety of bevacizumab 
and chemotherapy, either oxaliplatin or irinotecan, with 
or without panitumumab in the first-line setting [36]. A 
total of 823 and 230 patients were randomly assigned to 
the oxaliplatin and irinotecan cohorts, respectively. Pani-
tumumab was discontinued after a planned interim analy-
sis of 812 oxaliplatin patients that showed worse efficacy 
in the panitumumab arm. In the final analysis, panitu-
mumab was shown to reduce the progression-free sur-
vival from 11.4 months in the control arm to 10.0 months 
[HR, 1.27]. Subgroup analysis of the KRAS status also 
showed adverse outcomes in both wild-type and mutant 
subgroups with panitumumab. While the exact mecha-
nism of this unexpected finding was not clearly ex-
plained, the higher rate of toxicity in the panitumumab 
arm might be the main culprit. In the oxaliplatin cohort, 
an excess of grade 3/4 adverse events, including skin 
toxicity, diarrhea, infection and pulmonary embolism, 
was observed. 
Although the efficacy of concurrent cetuximab and 
bevacizumab seems encouraging in non-first line setting, 
concrete evidence from the two large phase III studies 
has suggested that this combination should not be applied 
outside clinical trial setting. 
3.2. Anti-EGFR Antibody Maintenance 
Although patients in most clinical trials are required to 
continue treatment till disease progression, in daily prac-
tice patients usually prefer “drug holiday” after initial 
disease control. The perceived benefit of a chemother-
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apy-free interval is the improved quality of life and re-
duced side effect from ongoing therapy. However, both 
the OPTIMOX2 [37] and the COIN study [38] have 
shown that a complete stop of chemotherapy would re-
sult in a shorter duration of disease control. The im-
proved toxicity profile has thus made target therapy an 
attractive option. 
In the NORDIC study [20], patients randomized to the 
intermittent-chemotherapy arm stopped the FLOX che-
motherapy after 16 weeks but continued cetuximab as 
maintenance therapy. FLOX chemotherapy was then rein-
troduced while continuing cetuximab upon disease pro-
gression. With this approach, the clinical outcomes in-
cluding the overall survival was similar to those patients 
on the continuous-chemotherapy arm. This is an early 
piece of evidence that maintenance therapy with cetuxi-
mab may be a feasible strategy and that further studies 
are warranted. 
3.3. Anti-EGFR Antibody beyond Progression 
Unlike the benefit of using bevacizumab beyond disease 
progression [39], data regarding the use of anti-EGFR 
antibodies in this setting is relatively limited. In the 
above mentioned study, the rate of post-study anti-EGFR 
antibodies therapy was 6% - 12% [13,16,20,24]. The 
post-hoc exploratory analysis of the EPIC study sug-
gested a potential clinical benefit of using cetuximab 
beyond disease progression [22]. Patients in the cetuxi-
mab-irinotecan arm who went on to receive cetuximab in 
the post-study therapy has a median survival of 16.2 
months [95% CI, 12.8 to 27.4 months] while those that 
did not receive any post-study therapy and those that 
received post-study therapy without cetuximab had me-
dian survival of 6.31 months [95% CI, 5.3 to 7.1 months] 
and 13.0 months [95% CI, 11.6 to 13.9 months]. Taking 
into account the selection bias inherent to this unplanned 
analysis, the result should be regarded as hypothesis- 
generating rather than practice changing and further 
studies are warranted. 
3.4. Anti-EGFR Antibody Rechallenge 
Based on the scientific data the KRAS status largely re-
mains the same during tumor progression [40] and that 
secondary KRAS mutations do not occur during anti- 
EGFR therapy [41], rechallenging patients with anti- 
EGFR antibody is another biologically plausible strategy 
in late-line therapy against KRAS wild-type tumor. 
A phase II prospective study was set up to evaluate the 
activity of rechallenge with cetuximab-based therapy 
[42]. Patients were retreated, after a new line of chemo-
therapy, with the same cetuximab and irinotecan-based 
regimen that they have benefited before. 39 patients were 
enrolled and the median number of prior therapies was 
four. The overall response rate was 53.8% including 2 
complete responses. The median progression-free sur-
vival was 6.6 months. 
Two smaller studies have investigated the efficacy of 
panitumumab monotherapy after cetuximab failure. The 
PANERB study was a single-arm, prospective, commu-
nity-based study that recruited 39 patients with KRAS 
wild-type tumor [43]. For patients that have responded to 
cetuximab-based therapy, subsequent panitumumab mono-
therapy was able to achieve a response rate of 54.5% and 
stable disease in 18.2% of patients. In case of cetuximab 
resistance, the response rate was 7.7% only. However, a 
second single-arm study that recruited 20 patients with 
unequivocal progression while on cetuximab showed 
somewhat inferior result [44]. No objective response was 
demonstrated and the stable disease rate was 45% with a 
median duration of only 1.7 months. 
Definitive evidence is lacking for the use of anti- 
EGFR antibody after cetuximab failure but it is sug-
gested a small subset of patients with KRAS wild-type 
tumor who had initial response to cetuximab-based ther-
apy might benefit from this approach. 
3.5. Anti-EGFR Antibody and Anti-VEGF  
Antibody as Sequential Therapy 
With the use of chemotherapy in metastatic colorectal 
cancer, it was shown that the exact sequence of chemo-
therapeutic agents used did not affect outcomes [45] as 
long as patients were exposed to all active agents [46]. 
However, there is no strong evidence to support the same 
principle in the use of anti- EGFR and anti- VEGF anti-
bodies. In fact, all clinical studies that support anti-EGFR 
and anti-VEFG antibody in non-first line setting were 
performed in era before the widespread use of these tar-
get therapies in the first-line setting [22,24,47]. In pre- 
clinical studies, cancer cells may become more depend-
ent on VEGF pathway when they acquired resistance to 
anti-EGFR therapy [48-50] and a sequence-specific clini-
cal benefit with these therapies would be a reasonable 
assumption. 
In the 20050181 study, around 20% of patients in each 
study arm have received bevacizumab before study entry. 
Patients were stratified according to previous bevacizu-
mab exposure and subgroup analysis on both progres-
sion-free survival and overall survival favored the addi-
tion of panitumumab irrespective of previous bevacizu-
mab exposure [24]. On the other hand, the effect of prior 
bevacizumab exposure on the efficacy of subsequent 
cetuximab treatment was explored in a small series of 
patients but prior bevacizumab exposure were associated 
with a significantly inferior outcome during subsequent 
cetuximab treatment [51]. 
There is no phase III study published yet to investiga-
tion specifically the clinical effect of sequential use of  
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anti-EGFR antibody and anti-VEGF antibody. The so- 
called FIRE3 study by the German AIO group may pro-
vide insight in this respect [52]. The study compared the 
efficacy for cetuximab plus FOLFIRI versus bevacizu-
mab plus FOLFIRI in the first-line treatment. The sec-
ond-line treatment was not randomized but data was 
captured. Only the result in the KRAS mutant subgroup 
has been reported while the result in the KRAS wild-type 
subgroup is still awaited. 
4. Conclusions 
It took almost two decades for anti-EGFR monoclonal 
antibody from bench to bedside. The ability to select 
patients according to KRAS mutational status has revo-
lutionalized the field of personalized therapy in the 
treatment of metastatic colorectal cancer. In the majority 
of clinical trials, anti-EGFR monoclonal antibody has 
proven efficacy and enhanced benefit is seen in KRAS 
wild-type tumor. The few studies that reported “uncon-
ventional” results should be viewed as an opportunity to 
further refine current treatment strategy in the context of 
previously-established evidence.  
With the best available evidence, the following can be 
concluded: 
Selection of patients: 
Anti-EGFR antibodies should only be used in patients 
with KRAS wild-type tumor [14,16,19,24,27,29]. The 
consistent improvement in response rate across all lines 
of treatment favors their use especially in patient with 
potentially resectable disease as well as patients with 
high tumor burden and significant tumor-related symp-
toms. 
Selection of chemotherapy partners:  
Irinotecan would be a robust choice [13,22,24,25]. The 
evidence of combining an anti-EGFR antibody with ox-
aliplatin is less clear and sometimes conflicting [16,17, 
19,20]. The use of infusional 5FU is preferred to bolus 
5FU or capecitabine as clinical benefit was demonstrated 
only with the former [13,16,24] while increased toxicity 
and even reduced clinical efficacy were seen with the 
latter [19,20]. 
Combining with anti-VEGF antibodies: 
Concurrent administration of anti-EGFR and anti- 
VEGF antibodies should be prohibited in routine clinical 
practice [35,36]. There is no recommendation on the se-
quential use of these antibodies and more studies are en-
couraged in the future. 
Selection of novel strategy: 
With the limited number of available agents against 
metastatic colorectal cancer, maximizing benefit of each 
agent is of utmost importance. The use of anti-EGFR 
antibodies in maintenance and rechallenge settings are 
both promising. However, their use beyond progression 
appears to have limited role.  
In the years to come, improved knowledge of the 
mechanism of resistance and interaction with other target 
therapies as well as chemotherapeutic agents would help 
define an optimal strategy in the treatment of metastatic 
colorectal cancer with anti-EGFR monoclonal antibody. 
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